Checkpoint inhibitors have shown limited efficacy in ALK+ metastatic non-small cell lung cancer (mNSCLC), but could a different immunologic strategy complement targeted therapy? Dr. Angel Qin discusses the rationale for ALK vaccines and explains how harnessing an ALK-specific immune response may help extend the durability of ALK TKI therapy. She's a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
